
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed is a promising investment opportunity due to its strong clinical data, potential for growth and profitability, and favorable economics of its personalized spine implants. The company's financials are robust, with increasing revenue and a growing base of active surgeons, although competitive risks and delays in hospital adoption may pose a challenge. Overall, the potential for Carlsmed to expand into new markets and launch new products makes it a sound investment option with a positive outlook.
Bears say
Carlsmed is a commercial-stage medical device company that has seen solid growth in recent quarters, however, their financials show a negative year-over-year trend with revenues declining from $5.8 million in 2025 to $5.3 million in 2026. The company's revenue is heavily reliant on physician utilization of its AI-enabled personalized solutions, which may face challenges in adoption and competition from other traditional spine fusion procedures. Additionally, the company's high costs for AI technology and ongoing R&D could lead to significant cash burn in the near future.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares